Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine (Q81570162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Anthony D Cristillo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Shixia Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Michael S Caskey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Tami Unangst

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Lindsey Hocker

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Leilei He

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Lauren Hudacik

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Stephen Whitney

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Tim Keen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Te-Hui W Chou

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Siyuan Shen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Swati Joshi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Vaniambadi S Kalyanaraman

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Balachandran Nair

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Phillip Markham

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Ranajit Pal

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

2 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

346

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

151-168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Long-term persistence of HIV-1 vaccine-induced CD4+CD45RA-CD62L-CCR7- memory T-helper cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Helping the CD8(+) T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

MHC polymorphism: AIDS susceptibility in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Relationship between the immune response and protection conferred by new designed inactivated vaccines against ovine enzootic abortion in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

DNA vaccines against human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunopathogenic mechanisms of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Development of a DNA-MVA/HIVA vaccine for Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunopathogenesis and immunotherapy in AIDS virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Virological rebound after suppression on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Immune responses and protection induced by DNA vaccines encoding bovine parainfluenza virus type 3 glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Enhancement of mucosal immune response against HIV-1 Gag by DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.10.038

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16325880%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference